Compare · ARGX vs BHSE
ARGX vs BHSE
Side-by-side comparison of argenx SE (ARGX) and Bull Horn Holdings Corp. (BHSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and BHSE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.42B, about 516.0x BHSE ($93.8M).
- ARGX has hit the wire 2 times in the past 4 weeks while BHSE has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 0 for BHSE).
- Company
- argenx SE
- Bull Horn Holdings Corp.
- Price
- $780.08-1.00%
- $12.50+50.42%
- Market cap
- $48.42B
- $93.8M
- 1M return
- +11.90%
- -
- 1Y return
- +25.72%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Bull Horn Holdings Corp.
Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE
Latest BHSE
- SEC Form SC 13G filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)
- New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)
- Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)
- Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)
- Salkind Gene bought $8,004 worth of shares (11,600 units at $0.69), increasing direct ownership by 4% to 284,056 units (SEC Form 4)
- Mehalick David bought $16,747 worth of shares (25,054 units at $0.67), increasing direct ownership by 0.91% to 2,782,615 units (SEC Form 4)